<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34051439</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2352-3964</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><PubDate><Year>2021</Year><Month>Jun</Month></PubDate></JournalIssue><Title>EBioMedicine</Title><ISOAbbreviation>EBioMedicine</ISOAbbreviation></Journal><ArticleTitle>Physical exercise is a risk factor for amyotrophic lateral sclerosis: Convergent evidence from Mendelian randomisation, transcriptomics and risk genotypes.</ArticleTitle><Pagination><StartPage>103397</StartPage><MedlinePgn>103397</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">103397</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ebiom.2021.103397</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2352-3964(21)00190-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Amyotrophic lateral sclerosis (ALS) is a universally fatal neurodegenerative disease. ALS is determined by gene-environment interactions and improved understanding of these interactions may lead to effective personalised medicine. The role of physical exercise in the development of ALS is currently controversial.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">First, we dissected the exercise-ALS relationship in a series of two-sample Mendelian randomisation (MR) experiments. Next we tested for enrichment of ALS genetic risk within exercise-associated transcriptome changes. Finally, we applied a validated physical activity questionnaire in a small cohort of genetically selected ALS patients.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">We present MR evidence supporting a causal relationship between genetic liability to frequent and strenuous leisure-time exercise and ALS using a liberal instrument (multiplicative random effects IVW, p=0.01). Transcriptomic analysis revealed that genes with altered expression in response to acute exercise are enriched with known ALS risk genes (permutation test, p=0.013) including C9ORF72, and with ALS-associated rare variants of uncertain significance. Questionnaire evidence revealed that age of onset is inversely proportional to historical physical activity for C9ORF72-ALS (Cox proportional hazards model, Wald test p=0.007, likelihood ratio test p=0.01, concordance=74%) but not for non-C9ORF72-ALS. Variability in average physical activity was lower in C9ORF72-ALS compared to both non-C9ORF72-ALS (F-test, p=0.002) and neurologically normal controls (F-test, p=0.049) which is consistent with a homogeneous effect of physical activity in all C9ORF72-ALS patients.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Our MR approach suggests a positive causal relationship between ALS and physical exercise. Exercise is likely to cause motor neuron injury only in patients with a risk-genotype. Consistent with this we have shown that ALS risk genes are activated in response to exercise. In particular, we propose that G4C2-repeat expansion of C9ORF72 predisposes to exercise-induced ALS.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">We acknowledge support from the Wellcome Trust (JCK, 216596/Z/19/Z), NIHR (PJS, NF-SI-0617-10077; IS-BRC-1215-20017) and NIH (MPS, CEGS&#xa0;5P50HG00773504,&#xa0;1P50HL083800, 1R01HL101388, 1R01-HL122939, S10OD025212, P30DK116074, and UM1HG009442).</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Author(s). Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Julian</LastName><ForeName>Thomas H</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glascow</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barry</LastName><ForeName>A Dylan Fisher</ForeName><Initials>ADF</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moll</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harvey</LastName><ForeName>Calum</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klimentidis</LastName><ForeName>Yann C</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of Arizona, Tucson, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newell</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of Arizona, Tucson, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Sai</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA; Center for Genomics and Personalized Medicine, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snyder</LastName><ForeName>Michael P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA; Center for Genomics and Personalized Medicine, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper-Knock</LastName><ForeName>Johnathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Pamela J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK. Electronic address: pamela.shaw@sheffield.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>S10 OD025212</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL101388</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 HL083800</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK116074</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL122939</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UM1 HG009442</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>EBioMedicine</MedlineTA><NlmUniqueID>101647039</NlmUniqueID><ISSNLinking>2352-3964</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>EBioMedicine. 2021 Jul;69:103438</RefSource><PMID Version="1">34157488</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015444" MajorTopicYN="N">Exercise</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059647" MajorTopicYN="N">Gene-Environment Interaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056726" MajorTopicYN="N">Genetic Association Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057182" MajorTopicYN="N">Mendelian Randomization Analysis</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">C9ORF72</Keyword><Keyword MajorTopicYN="N">Mendelian randomisation</Keyword><Keyword MajorTopicYN="N">Physical exercise</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest M.P.S. is a cofounder of Personalis, Qbio, Sensomics, Filtricine, Mirvie and January. He is on the scientific advisory board of these companies and Genapsys. No other authors have competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>4</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>29</Day><Hour>20</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34051439</ArticleId><ArticleId IdType="pmc">PMC8170114</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2021.103397</ArticleId><ArticleId IdType="pii">S2352-3964(21)00190-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown R.H., Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377:162&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J., Jenkins T., Shaw P.J. Biota Publishing; 2013. Clinical and molecular aspects of motor neuron disease.</Citation></Reference><Reference><Citation>Ryan M., Heverin M., McLaughlin R.L., Hardiman O. Lifetime risk and heritability of amyotrophic lateral sclerosis. JAMA Neurol. 2019 doi: 10.1001/jamaneurol.2019.2044. https://doi.org/</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.2044</ArticleId><ArticleId IdType="pmc">PMC6646974</ArticleId><ArticleId IdType="pubmed">31329211</ArticleId></ArticleIdList></Reference><Reference><Citation>Trabjerg B.B., Garton F.C., van Rheenen W., Fang F., Henderson R.D., Mortensen P.B. ALS in Danish Registries: Heritability and links to psychiatric and cardiovascular disorders. Neurol Genet. 2020;6:e398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7073454</ArticleId><ArticleId IdType="pubmed">32211514</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A., Calvo A., Chio A., Colville S., Ellis C.M., Hardiman O. Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Lancet Neurol. 2014;13:1108&#x2013;1113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4197338</ArticleId><ArticleId IdType="pubmed">25300936</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A., Mazzini L., D'Alfonso S., Corrado L., Canosa A., Moglia C. The multistep hypothesis of ALS revisited: the role of genetic mutations. Neurology. 2018;91:e635&#x2013;e642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6105040</ArticleId><ArticleId IdType="pubmed">30045958</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A., Calvo A., Dossena M., Ghiglione P., Mutani R., Mora G. ALS in Italian professional soccer players: the risk is still present and could be soccer-specific. Amyotroph Lateral Scler. 2009;10:205&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pubmed">19267274</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamidou B., Couratier P., Besan&#xe7;on C., Nicol M., Preux P.M., Marin B. Epidemiological evidence that physical activity is not a risk factor for ALS. Eur J Epidemiol. 2014;29:459&#x2013;475. doi: 10.1007/s10654-014-9923-2. https://doi.org/</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-014-9923-2</ArticleId><ArticleId IdType="pubmed">24986107</ArticleId></ArticleIdList></Reference><Reference><Citation>Harwood C.A., Westgate K., Gunstone S., Brage S., Wareham N.J., McDermott C.J. Long-term physical activity: an exogenous risk factor for sporadic amyotrophic lateral sclerosis? Amyotroph Lateral Scler Frontotemporal Degener. 2016;17:377&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4950417</ArticleId><ArticleId IdType="pubmed">26998882</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacorte E., Ferrigno L., Leoncini E., Corbo M., Boccia S., Vanacore N. Physical activity, and physical activity related to sports, leisure and occupational activity as risk factors for ALS: a systematic review. Neurosci Biobehav Rev. 2016;66:61&#x2013;79. doi: 10.1016/j.neubiorev.2016.04.007. https://doi.org/</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2016.04.007</ArticleId><ArticleId IdType="pubmed">27108217</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandres-Ciga S., Noyce A.J., Hemani G., Nicolas A., Calvo A., Mora G. Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Ann Neurol. 2019;85:470&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6450729</ArticleId><ArticleId IdType="pubmed">30723964</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M., Mackenzie I.R., Boeve B.F., Boxer A.L., Baker M., Rutherford N.J. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J., Hewitt C., Highley J.R., Brockington A., Milano A., Man S. Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72. Brain. 2012;135:751&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3286332</ArticleId><ArticleId IdType="pubmed">22366792</ArticleId></ArticleIdList></Reference><Reference><Citation>Majounie E., Renton A.E., Mok K., Dopper E.G.P., Waite A., Rollinson S. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 2012;11:323&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322422</ArticleId><ArticleId IdType="pubmed">22406228</ArticleId></ArticleIdList></Reference><Reference><Citation>Karpati G., Hilton-Jones D., Griggs R.C., Bushby K. Cambridge University Press; 2008. Disorders of voluntary muscle.</Citation></Reference><Reference><Citation>Nijssen J., Comley L.H., Hedlund E. Motor neuron vulnerability and resistance in amyotrophic lateral sclerosis. Acta Neuropathol. 2017;133:863.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5427160</ArticleId><ArticleId IdType="pubmed">28409282</ArticleId></ArticleIdList></Reference><Reference><Citation>Ragagnin A.M.G., Shadfar S., Vidal M., Jamali M.S., Atkin J.D. Motor neuron susceptibility in ALS/FTD. Front Neurosci. 2019;13:532.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6610326</ArticleId><ArticleId IdType="pubmed">31316328</ArticleId></ArticleIdList></Reference><Reference><Citation>Huisman M.H.B., Seelen M., de Jong S.W., Dorresteijn K.R.I.S., van Doormaal P.T.C., van der Kooi A.J. Lifetime physical activity and the risk of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2013;84:976&#x2013;981.</Citation><ArticleIdList><ArticleId IdType="pubmed">23418211</ArticleId></ArticleIdList></Reference><Reference><Citation>Clays E., De Bacquer D., Van Herck K., De Backer G., Kittel F., Holtermann A. Occupational and leisure time physical activity in contrasting relation to ambulatory blood pressure. BMC Public Health. 2012;12:1002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3551777</ArticleId><ArticleId IdType="pubmed">23164344</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess S., Smith G.D., Davies N.M., Dudbridge F., Gill D., Maria Glymour M. Guidelines for performing Mendelian randomization investigations. Wellcome Open Res. 2019;4 doi: 10.12688/wellcomeopenres.15555.2. https://doi.org/</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/wellcomeopenres.15555.2</ArticleId><ArticleId IdType="pmc">PMC7384151</ArticleId><ArticleId IdType="pubmed">32760811</ArticleId></ArticleIdList></Reference><Reference><Citation>Klimentidis Y.C., Raichlen D.A., Bea J., Garcia D.O., Wineinger N.E., Mandarino L.J. Genome-wide association study of habitual physical activity in over 377,000 UK Biobank participants identifies multiple variants including CADM2 and APOE. Int J Obes. 2018;42:1161&#x2013;1176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6195860</ArticleId><ArticleId IdType="pubmed">29899525</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell R., Elsworth B.L., Mitchell R., Raistrick C.A., Paternoster L., Hemani G., et&#xa0;al. MRC IEU UK Biobank GWAS pipeline version 2 2019. https://doi.org/ 10.5523/BRIS.PNOAT8CXO0U52P6YNFAEKEIGI.</Citation></Reference><Reference><Citation>Doherty A., Smith-Byrne K., Ferreira T., Holmes M.V., Holmes C., Pulit S.L. GWAS identifies 14 loci for device-measured physical activity and sleep duration. Nat Commun. 2018;9:5257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6288145</ArticleId><ArticleId IdType="pubmed">30531941</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Y., Day F.R., Gustafsson S., Buchkovich M.L., Na J., Bataille V. New loci for body fat percentage reveal link between adiposity and cardiometabolic disease risk. Nat Commun. 2016;7:10495.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4740398</ArticleId><ArticleId IdType="pubmed">26833246</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J.J., Wedow R., Okbay A., Kong E., Maghzian O., Zacher M. Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals. Nat Genet. 2018;50:1112&#x2013;1121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6393768</ArticleId><ArticleId IdType="pubmed">30038396</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rheenen W., Shatunov A., Dekker A.M., McLaughlin R.L., Diekstra F.P., Pulit S.L. Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nat Genet. 2016;48:1043&#x2013;1048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5556360</ArticleId><ArticleId IdType="pubmed">27455348</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J., Zaitlen N.A., Goddard M.E., Visscher P.M., Price A.L. Advantages and pitfalls in the application of mixed-model association methods. Nat Genet. 2014;46:100&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3989144</ArticleId><ArticleId IdType="pubmed">24473328</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi K.W., Chen C.-Y., Stein M.B., Klimentidis Y.C., Wang M.-J., Koenen K.C. Assessment of bidirectional relationships between physical activity and depression among adults: A 2-sample mendelian randomization study. JAMA Psychiatry. 2019;76:399&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6450288</ArticleId><ArticleId IdType="pubmed">30673066</ArticleId></ArticleIdList></Reference><Reference><Citation>Wootton R.E., Lawn R.B., Millard L.A.C., Davies N.M., Taylor A.E., Munaf&#xf2; M.R. Evaluation of the causal effects between subjective wellbeing and cardiometabolic health: Mendelian randomisation study. BMJ. 2018;362:k3788.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6155050</ArticleId><ArticleId IdType="pubmed">30254091</ArticleId></ArticleIdList></Reference><Reference><Citation>Purcell S., Neale B., Todd-Brown K., Thomas L., Ferreira M.A.R., Bender D. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1950838</ArticleId><ArticleId IdType="pubmed">17701901</ArticleId></ArticleIdList></Reference><Reference><Citation>Machiela M.J., Chanock S.J. LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics. 2015;31:3555&#x2013;3557.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4626747</ArticleId><ArticleId IdType="pubmed">26139635</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartwig F.P., Davies N.M., Hemani G., Davey Smith G. Two-sample Mendelian randomization: avoiding the downsides of a powerful, widely applicable but potentially fallible technique. Int J Epidemiol. 2016;45:1717&#x2013;1726.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5722032</ArticleId><ArticleId IdType="pubmed">28338968</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess S., Thompson S.G. Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol. 2017;32:377&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5506233</ArticleId><ArticleId IdType="pubmed">28527048</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess S., Thompson S.G., CRP CHD Genetics Collaboration Avoiding bias from weak instruments in Mendelian randomization studies. Int J Epidemiol. 2011;40:755&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pubmed">21414999</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowden J., Hemani G., Smith G.D. Invited commentary: detecting individual and global horizontal pleiotropy in mendelian randomization&#x2014;a job for the humble heterogeneity statistic? Am J Epidemiol. 2018 doi: 10.1093/aje/kwy185. https://doi.org/</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwy185</ArticleId><ArticleId IdType="pmc">PMC6269239</ArticleId><ArticleId IdType="pubmed">30188969</ArticleId></ArticleIdList></Reference><Reference><Citation>Verbanck M., Chen C.-Y., Neale B., Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018;50:693&#x2013;698.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6083837</ArticleId><ArticleId IdType="pubmed">29686387</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowden J., Del Greco M.F., Minelli C., Smith G.D., Sheehan N.A., Thompson J.R. Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I2 statistic. Int J Epidemiol. 2016:dyw220. doi: 10.1093/ije/dyw220. https://doi.org/</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyw220</ArticleId><ArticleId IdType="pmc">PMC5446088</ArticleId><ArticleId IdType="pubmed">27616674</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulik-Sullivan B.K., Schizophrenia Working Group of the Psychiatric Genomics Consortium, Loh P.-R., Finucane H.K., Ripke S., Yang J. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat Genet. 2015;47:291&#x2013;295. doi: 10.1038/ng.3211. https://doi.org/</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3211</ArticleId><ArticleId IdType="pmc">PMC4495769</ArticleId><ArticleId IdType="pubmed">25642630</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulik-Sullivan B., Consortium ReproGen, Finucane H.K., Anttila V., Gusev A., Day F.R. An atlas of genetic correlations across human diseases and traits. Nat Genet. 2015;47:1236&#x2013;1241. doi: 10.1038/ng.3406. https://doi.org/</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3406</ArticleId><ArticleId IdType="pmc">PMC4797329</ArticleId><ArticleId IdType="pubmed">26414676</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaughlin R.L., Schijven D., van Rheenen W., van Eijk K.R., O'Brien M., Kahn R.S. Genetic correlation between amyotrophic lateral sclerosis and schizophrenia. Nat Commun. 2017;8:14774.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5364411</ArticleId><ArticleId IdType="pubmed">28322246</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S., Abecasis G.R., Boehnke M., Lin X. Rare-variant association analysis: study designs and statistical tests. Am J Hum Genet. 2014;95:5&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4085641</ArticleId><ArticleId IdType="pubmed">24995866</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirulli E.T., Goldstein D.B. Uncovering the roles of rare variants in common disease through whole-genome sequencing. Nat Rev Genet. 2010;11:415&#x2013;425.</Citation><ArticleIdList><ArticleId IdType="pubmed">20479773</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Spek R.A.A., Van Rheenen W., Pulit S.L., Kenna K.P., van den Berg L.H., Veldink J.H. The Project MinE databrowser: bringing large-scale whole-genome sequencing in ALS to researchers and the public. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:432&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7893599</ArticleId><ArticleId IdType="pubmed">31280677</ArticleId></ArticleIdList></Reference><Reference><Citation>Contrepois K., Wu S., Moneghetti K.J., Hornburg D., Ahadi S., Tsai M.-S. Molecular Choreography of Acute Exercise. Cell. 2020;181:1112&#x2013;1130. .e16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7299174</ArticleId><ArticleId IdType="pubmed">32470399</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheffield Children's NHS Foundation Trust  . Sheffield Children's NHS Foundation Trust; 2019. Next Generation Sequencing Service at SDGS.https://www.sheffieldchildrens.nhs.uk/download/321/ngs/9291/next-generation-sequencing-v7.pdf (accessed April 11, 2020)</Citation></Reference><Reference><Citation>Besson H., Harwood C.A., Ekelund U., Finucane F.M., McDermott C.J., Shaw P.J. Validation of the historical adulthood physical activity questionnaire (HAPAQ) against objective measurements of physical activity. Int J Behav Nutr Phys Act. 2010;7:54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2902409</ArticleId><ArticleId IdType="pubmed">20576086</ArticleId></ArticleIdList></Reference><Reference><Citation>Ainsworth B.E., Haskell W.L., Herrmann S.D., Meckes N., Bassett D.R., Jr, Tudor-Locke C. 2011 Compendium of Physical Activities: a second update of codes and MET values. Med Sci Sports Exerc. 2011;43:1575&#x2013;1581.</Citation><ArticleIdList><ArticleId IdType="pubmed">21681120</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker V.M., Davies N.M., Hemani G., Zheng J., Haycock P.C., Gaunt T.R. Using the MR-Base platform to investigate risk factors and drug targets for thousands of phenotypes. Wellcome Open Res. 2019;4:113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6694718</ArticleId><ArticleId IdType="pubmed">31448343</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers T.A., Chanock S.J., Machiela M.J. LDlinkR: an R package for rapidly calculating linkage disequilibrium statistics in diverse populations. Front Genet. 2020;11:157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7059597</ArticleId><ArticleId IdType="pubmed">32180801</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariosa D., Beard J.D., Umbach D.M., Bellocco R., Keller J., Peters T.L. Body mass index and amyotrophic lateral sclerosis: a study of US military veterans. Am J Epidemiol. 2017;185:362&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5860019</ArticleId><ArticleId IdType="pubmed">28158443</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng P., Yu X., Xu H. Association between premorbid body mass index and amyotrophic lateral sclerosis: causal inference through genetic approaches. Front Neurol. 2019;10:543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6543002</ArticleId><ArticleId IdType="pubmed">31178821</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin B., Boum&#xe9;diene F., Logroscino G., Couratier P., Babron M.-C., Leutenegger A.L. Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta-analysis. Int J Epidemiol. 2017;46:57&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5407171</ArticleId><ArticleId IdType="pubmed">27185810</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaldivar T., Gutierrez J., Lara G., Carbonara M., Logroscino G., Hardiman O. Reduced frequency of ALS in an ethnically mixed population: a population-based mortality study. Neurology. 2009;72:1640&#x2013;1645.</Citation><ArticleIdList><ArticleId IdType="pubmed">19433736</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T., Cudkowicz M., Shaw P.J., Andersen P.M., Atassi N., Bucelli R.C. Phase 1&#x2013;2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2020;383:109&#x2013;119. doi: 10.1056/nejmoa2003715. https://doi.org/</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa2003715</ArticleId><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess S., Bowden J., Fall T., Ingelsson E., Thompson S.G. Sensitivity analyses for robust causal inference from mendelian randomization analyses with multiple genetic variants. Epidemiology. 2017;28:30&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5133381</ArticleId><ArticleId IdType="pubmed">27749700</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtermann A., Krause N., van der Beek A.J., Straker L. The physical activity paradox: six reasons why occupational physical activity (OPA) does not confer the cardiovascular health benefits that leisure time physical activity does. Br J Sports Med. 2018;52:149&#x2013;150. doi: 10.1136/bjsports-2017-097965. https://doi.org/</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bjsports-2017-097965</ArticleId><ArticleId IdType="pubmed">28798040</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhan Y., Fang F. Smoking and amyotrophic lateral sclerosis: a Mendelian randomization study. Ann Neurol. 2019;85:482&#x2013;484.</Citation><ArticleIdList><ArticleId IdType="pubmed">30786056</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng P., Wang T., Zheng J., Zhou X. Causal association of type 2 diabetes with amyotrophic lateral sclerosis: new evidence from Mendelian randomization using GWAS summary statistics. BMC Med. 2019;17:225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6892209</ArticleId><ArticleId IdType="pubmed">31796040</ArticleId></ArticleIdList></Reference><Reference><Citation>McKee A.C., Gavett B.E., Stern R.A., Nowinski C.J., Cantu R.C., Kowall N.W. TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. J Neuropathol Exp Neurol. 2010;69:918&#x2013;929.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2951281</ArticleId><ArticleId IdType="pubmed">20720505</ArticleId></ArticleIdList></Reference><Reference><Citation>Opie-Martin S., Wootton R.E., Budu-Aggrey A., Shatunov A., Jones A.R., Iacoangeli A. Relationship between smoking and ALS: Mendelian randomisation interrogation of causality. J Neurol Neurosurg Psychiatry. 2020;91:1312&#x2013;1315.</Citation><ArticleIdList><ArticleId IdType="pubmed">32848012</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies N.M., Holmes M.V., Davey Smith G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ. 2018;362:k601.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6041728</ArticleId><ArticleId IdType="pubmed">30002074</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadaka A.S., Faisal A., Khalil Y.M., Mourad S.M., Zidan M.H., Polkey M.I. Reduced skeletal muscle endurance and ventilatory efficiency during exercise in adult smokers without airflow obstruction. J Appl Physiol. 2021 doi: 10.1152/japplphysiol.00762.2020. https://doi.org/</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/japplphysiol.00762.2020</ArticleId><ArticleId IdType="pubmed">33444125</ArticleId></ArticleIdList></Reference><Reference><Citation>Amanat S., Ghahri S., Dianatinasab A., Fararouei M., Dianatinasab M. Exercise and type 2 diabetes. Adv Exp Med Biol. 2020;1228:91&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">32342452</ArticleId></ArticleIdList></Reference><Reference><Citation>Cassina P., Pehar M., Vargas M.R., Castellanos R., Barbeito A.G., Est&#xe9;vez A.G. Astrocyte activation by fibroblast growth factor-1 and motor neuron apoptosis: implications for amyotrophic lateral sclerosis. J Neurochem. 2005;93:38&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">15773903</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbeito L.H., Pehar M., Cassina P., Vargas M.R., Peluffo H., Viera L. A role for astrocytes in motor neuron loss in amyotrophic lateral sclerosis. Brain Res Brain Res Rev. 2004;47:263&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">15572176</ArticleId></ArticleIdList></Reference><Reference><Citation>Houtz J., Borden P., Ceasrine A., Minichiello L., Kuruvilla R. Neurotrophin signaling is required for glucose-induced insulin secretion. Dev Cell. 2016;39:329&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5123838</ArticleId><ArticleId IdType="pubmed">27825441</ArticleId></ArticleIdList></Reference><Reference><Citation>Canosa A., D'Ovidio F., Calvo A., Moglia C., Manera U., Torrieri M.C. Lifetime sport practice and brain metabolism in Amyotrophic Lateral Sclerosis. Neuroimage Clin. 2020;27</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7334468</ArticleId><ArticleId IdType="pubmed">32622315</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J., Shaw P.J., Kirby J. The widening spectrum of C9ORF72-related disease; genotype/phenotype correlations and potential modifiers of clinical phenotype. Acta Neuropathol. 2014;127:333&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3925297</ArticleId><ArticleId IdType="pubmed">24493408</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J., Higginbottom A., Connor-Robson N., Bayatti N., Bury J.J., Kirby J. C9ORF72 transcription in a frontotemporal dementia case with two expanded alleles. Neurology. 2013;81:1719&#x2013;1721.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3812108</ArticleId><ArticleId IdType="pubmed">24107864</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>